Core Viewpoint - Shanghai Heyu Biopharmaceutical Technology Co., Ltd. announced that its self-developed oral and highly selective small molecule CSF-1R inhibitor, Beijiemai (pimitinib hydrochloride capsules), has received formal acceptance of its New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for the systemic treatment of patients with tenosynovial giant cell tumors (TGCT) [1][2]. Group 1 - Beijiemai is a novel, oral, highly selective, and efficient small molecule CSF-1R inhibitor developed independently by the company [3]. - The NDA acceptance is based on positive results from the global multicenter, randomized, double-blind, placebo-controlled Phase III MANEUVER study, which showed a significant improvement in objective response rate (ORR) for TGCT patients treated with Beijiemai compared to the placebo group [2]. - All secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reduced stiffness and pain [2]. Group 2 - TGCT is a rare locally aggressive tumor that occurs in or around joints, leading to swelling, stiffness, and restricted movement, significantly impacting patients' daily activities and quality of life [2]. - Beijiemai has already been approved by the National Medical Products Administration (NMPA) in China for symptomatic TGCT adult patients who may experience functional limitations or severe complications from surgical resection [3]. - The company has reached an agreement with Merck for the global commercialization rights of Beijiemai, which has also received breakthrough therapy designation (BTD) from the FDA and priority medicine (PRIME) designation from the European Medicines Agency (EMA) [3].

Core Viewpoint - The new drug application (NDA) for the oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijiemai (Pimicitin Hydrochloride Capsules), developed by He Yu Pharmaceutical, has been officially accepted by the FDA for the systemic treatment of patients with tenosynovial giant cell tumor (TGCT) [1][2] Group 1: Drug Development and Approval - Beijiemai has been developed by He Yu Pharmaceutical and licensed to Merck for global commercialization [1] - The drug received approval from the National Medical Products Administration (NMPA) in China in December 2025 for symptomatic TGCT adult patients who may experience functional limitations or severe complications from surgical removal [1] - The NDA acceptance by the FDA is based on positive results from the global multicenter, randomized, double-blind, placebo-controlled Phase III MANEUVER study [2] Group 2: Clinical Study Results - The study demonstrated that patients with TGCT treated with Beijiemai showed a significantly higher objective response rate (ORR) compared to the placebo group at week 25, as assessed by the blinded independent review committee (BIRC) using RECIST v1.1 criteria [2] - All secondary endpoints related to key clinical outcomes in TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reductions in stiffness and pain [2] - Long-term data with a median follow-up of 14.3 months indicated a continuous improvement in ORR for patients who started treatment with Beijiemai [2] Group 3: Disease Context and Market Potential - TGCT is a rare locally aggressive tumor occurring in or around joints, leading to swelling, stiffness, and restricted movement, significantly impacting patients' daily activities and quality of life [2] - If untreated or recurrent, TGCT can cause irreversible damage to bones, joints, and surrounding tissues [2] - With the ongoing submissions and future approvals in major global markets, Beijiemai is expected to provide an innovative treatment option that is effective, well-tolerated, and administered once daily, addressing the unmet clinical needs in this disease area [2]

Group 1 - The core viewpoint of the articles highlights the recent approvals of innovative drugs by HeYu Pharmaceutical, including the first systemic treatment for tenosynovial giant cell tumor (TGCT) in China and a KRAS G12D inhibitor for clinical trials [1][2] Group 2 - HeYu Pharmaceutical's CSF-1R inhibitor, Beijiemai (pimitinib hydrochloride capsules), has received approval from the National Medical Products Administration (NMPA), marking it as the first systemic treatment for TGCT in China [1] - The KRAS G12D inhibitor, ABSK141, has also received NMPA approval for an open-label Phase I/II clinical trial to evaluate its safety, tolerability, efficacy, and pharmacokinetics in patients with advanced solid tumors carrying the KRAS G12D mutation [1] - Preliminary data from the Phase II clinical study of the oral PD-L1 inhibitor ABSK043 in combination with the EGFR inhibitor Furmonertinib for non-small cell lung cancer (NSCLC) shows good safety and tolerability, with no observed dose-limiting toxicities or interstitial lung disease [2] - Revenue forecasts for HeYu Pharmaceutical are projected at 612.1 million, 678.8 million, and 627.2 million yuan for 2025-2027, reflecting year-on-year growth rates of 21.5%, 10.9%, and -7.6% respectively, with the current stock price corresponding to price-to-sales ratios of 13.0, 11.7, and 12.7 [2]

Investment Rating - The report does not explicitly state an investment rating for the biopharmaceutical industry, but it suggests a positive outlook based on upcoming catalysts and potential drug approvals. Core Insights - The biopharmaceutical sector is expected to see significant developments in 2026, with multiple domestic drugs anticipated to report key clinical data. This includes drugs from companies like Betta Pharmaceuticals, Hutchison China MediTech, and CanSino Biologics, which are expected to read out critical clinical data in 2026 [3][21]. - The report emphasizes that the long-term theme for the innovative drug sector is international expansion, with several sub-themes to focus on, including overseas business development (BD) licensing, key clinical trials, and unexpected overseas sales growth [3][18]. Summary by Sections Weekly New Drug Market Review - From December 22 to December 28, 2025, the top five gainers in the new drug sector were Dongyao Pharmaceutical (+23.15%), Beihai Kangcheng (+19.27%), Junshengtai (+16.41%), Shiyao Group (+6.95%), and Ailis (+5.78%). The top five losers were Gakos (-16.11%), Jiahe Biotech (-10.29%), Laika Pharmaceuticals (-9.33%), Yunding Xinyao (-8.98%), and Yongtai Biotech (-6.94%) [1][14]. Weekly Focused Stocks - The report suggests focusing on several stocks with high overseas expansion potential, including: 1. Companies with MNC certification and high overseas volume certainty: Sanofi, United Pharmaceuticals, and Kelun-Biotech. 2. Companies with overseas data catalysts: Betta Pharmaceuticals, Hutchison China MediTech, and InnoCare Pharma. 3. Potential heavyweights for overseas MNC licensing: Junshi Biosciences, Shiyao Group, and Yifang Biotech. 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat loss and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2][18]. Weekly New Drug Approval & Acceptance Status - This week, 23 new drug or new indication applications were approved in China, and 10 new drug or new indication applications were accepted [4][19]. Weekly New Drug Clinical Application Approval & Acceptance Status - This week, 99 new drug clinical applications were approved, and 64 new drug clinical applications were accepted [5][24]. Key Domestic Market Events - Notable events include: 1. Xiansheng Zhaoming announced a global exclusive licensing agreement with Ipsen for an ADC drug, potentially worth up to $1.06 billion. 2. He Yu Pharmaceuticals received approval for its CSF-1R selective small molecule inhibitor. 3. Tongyi Pharmaceuticals announced a licensing agreement for a peptide conjugate drug for prostate cancer, with potential payments totaling around $2 billion [10]. Key Overseas Market Events - Significant overseas events include: 1. Novo Nordisk received FDA approval for a 25mg oral semaglutide tablet for weight loss. 2. Sanofi announced a cash acquisition agreement for Dynavax Technologies Corporation, valued at approximately $2.2 billion. 3. Agios Pharmaceuticals announced FDA approval for an oral PK activator for treating α or β thalassemia in adult patients [11].

Core Viewpoint - The National Medical Products Administration (NMPA) has approved Bejimai (pimitidine hydrochloride capsules) for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adult patients, marking it as the first innovative drug approved for TGCT treatment in China [1][4]. Group 1: Drug Approval and Significance - Bejimai is a colony-stimulating factor-1 receptor inhibitor, providing a new treatment option for TGCT, a rare locally aggressive tumor that can lead to significant joint swelling, stiffness, and functional limitations [1][4]. - The approval is based on the positive results from the global Phase III MANEUVER study, which were presented at the 2025 American Society of Clinical Oncology Annual Meeting [4]. Group 2: Clinical Impact and Patient Needs - Many TGCT patients in China face treatment challenges, as there are limited options beyond surgery, particularly for those with tumor recurrence or inoperable cases [4]. - The approval of Bejimai offers clinicians the opportunity to provide an effective and well-tolerated systemic treatment option, representing progress in the management of this difficult-to-treat disease [4]. - The pain and activity limitations caused by TGCT significantly impact patients' daily lives, leading to considerable mental stress, highlighting the importance of effective treatment options like Bejimai [4].

Core Viewpoint - The approval of the drug by the NMPA represents a significant advancement for the treatment of symptomatic TGCT in adult patients, indicating potential market opportunities for the company in China [1] Group 1: Company Announcement - The company, He Yu-B (02256), announced that its subsidiary, Shanghai He Yu Biomedical Technology Co., Ltd. ("He Yu Pharmaceutical"), received approval from the National Medical Products Administration (NMPA) for the drug Beijiemai (Pimicotinib Hydrochloride Capsules) [1] - The approved indication is for adult patients with symptomatic tenosynovial giant cell tumors (TGCT) that may lead to functional limitations or serious complications following surgical removal [1] - Following the approval, Merck will expedite efforts to make the product available to TGCT patients in China [1]